已发表论文

呼吸与瓶:评估酒精使用障碍药物治疗对慢性阻塞性肺疾病急性加重结局的影响

 

Authors Zhang T, Ding Q, Liu M, Song Y , Zhang L, Liang N, Zhao X, Wang Q, Guo X, Yang G, Zhang H, Chen W

Received 25 February 2025

Accepted for publication 22 July 2025

Published 4 August 2025 Volume 2025:20 Pages 2697—2704

DOI https://doi.org/10.2147/COPD.S524905

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Richard Russell

Teng Zhang,1,* Qin Ding,2,* Mengmeng Liu,1 Yanning Song,1 Lvfeng Zhang,1 Na Liang,1 Xia Zhao,1 Qian Wang,1 Xueli Guo,1 Guangmei Yang,1 Hongwei Zhang,1 Wei Chen2 

1The Affiliated Encephalopathy Hospital of Zhengzhou University, Zhumadian, People’s Republic of China; 2Nutritional Department, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Hongwei Zhang, The Affiliated Encephalopathy Hospital of Zhengzhou University, Zhumadian, People’s Republic of China, Email hwzhang776@126.com Wei Chen, Nutritional Department, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, People’s Republic of China, Email cw13816728907@126.com

Background: The role of pharmacotherapy for alcohol use disorder (AUD) in mitigating COPD exacerbations remains underexplored. This study aims to evaluate the impact of AUD pharmacotherapy on COPD-related clinical outcomes.
Methods: A retrospective cohort study was conducted on 635 COPD patients with comorbid AUD. Patients were categorized into two groups based on whether they received medication for AUD (MAUD group) or not (no-MAUD group). Data on demographics, COPD severity, exacerbation rates, and AUD treatment were extracted from electronic medical records.
Results: Individuals in the MAUD group (n=229) exhibited a substantially reduced frequency of COPD exacerbations when compared to those in the non-MAUD group (n=406), with a significant difference observed (P< 0.001). Additionally, the MAUD group experienced a longer duration before the first exacerbation event (P< 0.001).
Conclusion: Pharmacotherapy for AUD appears to have a protective effect against the occurrence of COPD exacerbations and improved clinical outcomes in patients with comorbid AUD. These findings suggest that AUD treatment should be considered as part of a comprehensive management strategy for COPD patients with AUD.

Keywords: alcohol use disorder, chronic obstructive pulmonary disease, exacerbation, addiction treatment